In-Person Access Only | 6.00 CME Credits & MOC Points

Please read: All programs remain free. Registrations will require a credit card as a cancellation hold. A fee of $50 will only be incurred in the event of a no-show or cancellation within 5 days without written confirmation to the Total Health Program Team.

Total Health’s 2027 ASCO Direct™ Genitourinary Cancer Conference is an officially licensed ASCO Direct™ meeting. This Post-ASCO Genitourinary Cancers Symposium Review highlights key abstracts from top-rated presentations, providing attendees with direct access to the latest research and strategies in GU oncology education. The accredited meeting will be hosted as an in person meeting only available exclusively to registered participants.

Conference Agenda
Sunday, February 21, 2027

Program Chairs:
Alexander Wei, MD | Columbia University Irving Medical Center
Katie Murray, MD | NYU Langone

7:00 AM - 7:30 AM
Coffee and Exhibits

7:30 AM - 7:40 AM
Program Chair Welcome
Alexander Wei, MD | Columbia University Irving Medical Center
Katie Murray, MD | NYU Langone

7:40 AM - 8:10 AM
Evolving Perioperative Management of Bladder Cancer: Integrating Novel Therapies, ctDNA, and Emerging Evidence
Katie Murray, MD | NYU Langone

8:10 AM - 8:40 AM
Frontline Treatment of Advanced Urothelial Carcinoma: Current Standards and Emerging Strategies
Vadim Koshkin, MD | UCSF

8:40 AM - 9:10 AM
Treatment Sequencing in Metastatic Urothelial Carcinoma: Strategies Following Frontline Therapy
Alexander Wei, MD | Columbia University Irving Medical Center

9:10 AM - 9:40 AM
Breakfast and Exhibits

9:40 AM - 10:25 AM
Non-CME Breakfast

10:25 AM - 10:35 AM
Break and Refreshments

10:35 AM - 11:05 AM
Advancing Adjuvant and Frontline Therapy in Renal Cell Carcinoma: Emerging Evidence and Treatment Strategies
Tian Zhang, MD | UT Southwestern

11:05 AM - 11:35 AM
Precision Approaches in Prostate Cancer: Perioperative Strategies, Biomarkers, and Emerging Evidence
Christopher Evans, MD | Renown

11:35 AM - 12:15 PM
Decoding the Drivers of Decision-Making: Gaining Insight into Community Oncologists’ Implementation of Radioligand Therapy in the Management of Prostate Cancer

12:15 PM - 12:45 PM
Evolving Treatment Strategies in Advanced Prostate Cancer: Radiopharmaceuticals and Novel Systemic Approaches
Evan Yu, MD | University of Washington

12:45 PM - 1:05 PM
Lunch and Exhibits

1:05 PM - 1:50 PM
Non-CME Lunch

1:50 PM - 1:55 PM
Break and Exhibits

1:55 PM - 2:00 PM
Housekeeping and Survey

2:00 PM - 2:30 PM
Beyond Clear Cell RCC: Emerging Evidence and Treatment Strategies in Non-Clear Cell Renal Cell Carcinoma
Arpita Desai, MD | UCSF

2:30 PM - 3:00 PM
Treatment of Refractory Renal Cell Carcinoma: Current Options and Emerging Therapeutic Strategies
Sandy Srinivas, MD | Stanford University

3:00 PM - 3:15 PM
Managing Treatment-Related Toxicities in GU Oncology: Practical Strategies for Clinical Practice
Alexander Wei, MD | Columbia University Irving Medicla Center
Katie Murray, MD | NYU Langone

3:15 PM - 4:15 PM
Expert Roundtable: Applying Emerging Evidence to the Management of Renal Cell Carcinoma

4:15 PM
ADJOURN

‍ ‍ Agenda Subject To Change. All times are HST.

• Learning Objectives

  • Evaluate emerging clinical data and therapeutic advances across bladder, prostate, renal cell, and other genitourinary cancers to inform evidence-based treatment decisions.

  • Apply evolving evidence for perioperative, frontline, and later-line systemic therapies to optimize treatment selection and sequencing for patients with genitourinary malignancies.

  • Assess the clinical utility of prognostic and predictive biomarkers, including ctDNA, MRD, PTEN, and homologous recombination repair alterations, when individualizing treatment strategies for patients with GU cancers.

  • Integrate new and emerging treatment approaches, including antibody-drug conjugates, immunotherapies, targeted agents, radiopharmaceuticals, and novel combination regimens, into contemporary GU oncology practice.

  • Implement practical strategies for recognizing and managing treatment-related toxicities associated with contemporary GU cancer therapies to support safe, effective patient care.

• Accreditation Information

• What to Expect | In-Person Learners

  • Free registration for all healthcare providers

  • Expert sessions that present the most clinically relevant data, research, and clinical strategies

  • Real-time discussion and debate

  • Networking with peers, colleagues, and medical professionals

  • Access to the latest industry information and resources

  • Catered meals through-out the program